|Bid||88.12 x 1300|
|Ask||95.40 x 1000|
|Day's Range||90.25 - 92.19|
|52 Week Range||30.76 - 104.53|
|Beta (3Y Monthly)||2.91|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 9, 2017 - Aug 14, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||132.14|
Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -1.03% and -1.94%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Pivotal Trials CARDINAL and MOXIe Fully Enrolled and Data Expected in the Second Half of 2019 FALCON Pivotal Phase 3 Trial to Initiate in May 2019 Conference Call With.
The drug, bardoxolone, that Reata is developing to fight kidney disease has "striking efficacy," Bihua Chen says. Shares of Reata Pharmaceutical jump nearly 5% after Chen reveals her bet on the drugmaker. Bihua Chen, founder and portfolio manager at Cormorant Asset Management, said on Monday she likes Reata Pharmaceuticals RETA for the drug it's developing to fight kidney disease.
Bardoxolone methyl (bardoxolone) is an experimental, oral, once-daily activator of Nrf2, a transcription factor that induces molecular pathways that promote the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. The U.S. Food and Drug Administration has granted Orphan Drug designation to bardoxolone for the treatment of Alport syndrome and pulmonary arterial hypertension. The European Commission has granted Orphan Drug designation in Europe to bardoxolone for the treatment of Alport syndrome.
IRVING, Texas, May 02, 2019 -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and.
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips on the charts, usually don't make them change their opinion towards a company. This time it may be different. During the fourth quarter of 2018 we observed increased volatility and small-cap stocks underperformed the market. Hedge […]
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Reata Pharmaceuticals, Inc.'s (NASDAQ:RETA): Reata Pharmaceuticals, Inc., a clinical stage biop...
PIVOTAL TRIALS CARDINAL AND MOXIE FULLY ENROLLED WITH DATA EXPECTED SECOND HALF 2019 FALCON PIVOTAL PHASE 3 TRIAL TO INITIATE IN MID-2019 CONFERENCE CALL WITH MANAGEMENT.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! We often see insiders buying up shares in companies thatRead More...
Reata Pharmaceuticals, Inc. (RETA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IRVING, Texas, Feb. 21, 2019 -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results.
STATISTICALLY SIGNIFICANT IMPROVEMENT IN KIDNEY FUNCTION OBSERVED IN PATIENTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AFTER 12 WEEKS OF TREATMENT BARDOXOLONE METHYL.
NEW YORK,, Feb. 05, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced the appointment of Geoffrey A. Block, M.D., as Vice President, Nephrology. Dr. Block, a world-renowned nephrologist, joins Reata with over 20 years of experience conducting clinical research and treating patients with chronic kidney disease (CKD). Dr. Block served as the Director of Clinical Research in the Denver Nephrology Research Division at Colorado Kidney Care/Denver Nephrologists. Dr. Block has participated in multiple clinical studies of bardoxolone methyl (bardoxolone), Reata’s lead clinical candidate, and recently presented results from both the Phase 2 CARDINAL and Phase 2 PHOENIX trials of bardoxolone in rare forms of CKD at the American Society of Nephrology Kidney Week 2018.
In light of the recent volatility in the credit markets, it is more critical than ever to make sure small developmental firms have enough of a cash runway in place to avoid a financing crunch in the foreseeable future. The biotech sector seems ripe for some bargain hunting after small biotechs fell nearly 20% in 2019 after a sharp decline in the fourth quarter. Iovance's lead product candidate is an adoptive cell therapy using TIL (Tumor Infiltrating Lymphocytes) technology that is being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck, recurrent/metastatic or persistent cervical cancer and locally advanced or metastatic non-small cell lung cancer.
Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced that it has completed a successful end-of-Phase 2 meeting with the United States Food and Drug Administration (FDA) regarding the design of a Phase 3 clinical trial of bardoxolone methyl (bardoxolone) in patients with autosomal dominant polycystic kidney disease (ADPKD). The trial, named FALCON, will be an international, double-blind, placebo-controlled, parallel group, Phase 3 trial. The Company plans to enroll approximately 300 ADPKD patients randomized 1:1 to oral, once-daily bardoxolone or placebo. The trial will include ADPKD patients from 18 to 70 years old with an estimated glomerular filtration rate (eGFR) between 30 to 90 mL/min/1.73 m2. The primary efficacy endpoint is the change from baseline in eGFR compared to placebo after 48 weeks of treatment followed by a 4-week drug withdrawal period, the retained eGFR benefit.
Insider Monkey has processed numerous 13F filings of hedge funds and famous investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds and investors’ positions as of the end of the third quarter. You can find write-ups about an individual hedge fund’s trades on numerous financial news websites. […]
NEW YORK, Nov. 26, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -30.49% and -45.51%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?